View Older Stories View More Recent Stories

Sep 12, 2024 08:30AM Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial
Sep 10, 2024 08:02AM Gilead Sciences (GILD) and Genesis Therapeutics Enter Strategic Collaboration to Discover and Develop Novel Therapies
Sep 10, 2024 08:00AM Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies
Sep 5, 2024 08:07AM Gilead Sciences (GILD) to Present New Trodelvy Data at the IASLC 2024 World Conference on Lung Cancer
Sep 5, 2024 08:00AM Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer
Aug 21, 2024 04:05PM Gilead Sciences to Present at Upcoming Investor Conferences
Aug 14, 2024 01:59PM Gilead Sciences' (GILD) Livdelzi Granted Accelerated FDA Approval for Primary Biliary Cholangitis
Aug 14, 2024 01:59PM Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA
Jul 25, 2024 04:05PM Gilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
Jul 24, 2024 04:30AM Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024
Jul 17, 2024 08:50AM Gilead Sciences (GILD) Announces Upcoming Departure of Chief Medical Officer
Jul 17, 2024 08:50AM Chief Medical Officer Merdad Parsey to Leave Gilead Early 2025
Jun 20, 2024 08:51AM Gilead Sciences (GILD) Reports Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada for HIV Prevention
Jun 20, 2024 08:51AM Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention
Jun 20, 2024 08:45AM Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
Jun 2, 2024 08:00AM Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
Jun 1, 2024 08:00AM Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
May 22, 2024 08:30AM Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024
May 9, 2024 04:08PM Kite (GILD) and Arcellx (ACLX) Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
May 9, 2024 04:05PM Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
May 9, 2024 04:05PM Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
May 7, 2024 08:30AM Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
Apr 30, 2024 04:05PM Gilead Sciences to Present at Upcoming Investor Conferences
Apr 26, 2024 08:00AM FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV
Apr 8, 2024 04:05PM Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024
Mar 28, 2024 08:31AM FDA Expands Indication for Gilead's (GILD) Vemlidy to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
Mar 28, 2024 08:30AM FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
Mar 28, 2024 07:02AM Gilead Sciences (GILD) and Xilio (XLO) Enter Exclusive License Agreement for Tumor-Activated IL-12 Program
Mar 28, 2024 07:00AM Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
Mar 22, 2024 09:18AM Gilead Sciences (GILD) Announces Completion of Acquisition of CymaBay (CBAY)
Mar 22, 2024 09:18AM Gilead Sciences Announces Completion of Acquisition of CymaBay
Mar 11, 2024 08:24AM Gilead Sciences (GILD) Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay (CBAY) Tender Offer
Mar 11, 2024 08:24AM Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer
Mar 6, 2024 10:25AM Gilead Sciences (GILD) and Merck (MRK) Report Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
Mar 6, 2024 10:25AM Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
Mar 6, 2024 08:01AM Gilead Sciences (GILD), Merus (MRUS) Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
Mar 6, 2024 08:00AM Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
Mar 5, 2024 04:35PM Gilead Sciences (GILD) Reports New Real-World Data Supporting the Use of Veklury for People Hospitalized With COVID-19
Mar 5, 2024 04:35PM New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19
Mar 5, 2024 04:31PM Gilead Sciences (GILD) HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health
Mar 5, 2024 04:30PM Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health
Mar 5, 2024 07:03AM RedHill Biopharma's (RDHL) Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs
Mar 5, 2024 07:00AM RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs
Feb 28, 2024 05:15PM Gilead Announces Funding Initiative To Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.
Feb 27, 2024 10:00AM Gilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.
Feb 26, 2024 04:07PM Gilead Sciences (GILD) Announces FDA Approval of Expanded Indication for Biktarvy
Feb 26, 2024 04:05PM U.S. FDA Approves Expanded Indication for Gilead’s Biktarvy® to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance
Feb 26, 2024 08:33AM Gilead Sciences (GILD) to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024
Feb 26, 2024 08:30AM Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024
Feb 20, 2024 04:05PM Gilead Sciences to Present at Upcoming Investor Conferences
View More Recent Stories View Older Stories